CD39-L2 - Hyseq

Drug Profile

CD39-L2 - Hyseq

Latest Information Update: 15 Oct 2002

Price : $50

At a glance

  • Originator Nuvelo
  • Class Anticoagulants
  • Mechanism of Action Enzyme replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Myocardial infarction; Stroke

Most Recent Events

  • 15 Oct 2002 Discontinued - Preclinical for Stroke in USA (unspecified route)
  • 15 Oct 2002 Discontinued - Preclinical for Myocardial infarction in USA (unspecified route)
  • 05 Apr 2000 Preclinical development for Stroke in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top